William L. Moore
All posts from William L. Moore
William L. Moore in Insider trading,

Analysts Still Like Allergan

Following Allergan plc Ordinary Shares AGN second-quarter results, UBS still likes the company.

Analyst Marc Goodman said, despite the beat-and-raise quarter, investors are skeptical concerning the quality of the results. The analyst noted sales don't assume Namenda generics this year, with the company refraining from raising the top-line guidance due to concerns for Viberzi, Kybella and Aczone.

UBS noted the numbers got a boost from forex. Additionally, the increase in gross margin guidance is attributable to a one-time benefit arising from a tax refund, the firm added. Source

What goes to chart, there is still some upside potential due to stochastics.